Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups.
Svenja TonnAndrey KorshunovDenise ObrechtMartin SillMichael SpohnKatja von HoffTill MildeTorsten PietschTobias GoschzikBrigitte BisonBjörn-Ole JuhnkeNina StruveDominik SturmFelix SahmMichael BockmayrCarsten FriedrichAndré O von BuerenNicolas U GerberMartin BeneschDavid T W JonesMarcel KoolAnnika K WefersUlrich SchüllerStefan M PfisterStefan RutkowskiMartin MynarekPublished in: Neuro-oncology (2023)
These data suggest further heterogeneity within early childhood SHH-DMB/MBEN: SHH-2 splits into a very low-risk group SHH-2a enriched for MBEN histology and SMO mutations, and SHH-2b comprising older DMB patients with higher risk of relapse.